Topic: 

SGLT2i Inhibitors: A Dynamic and Evolving Therapeutic Option

Objectives:

• Describe the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the physiology of cardiorenal disease.
• Discuss the clinical effects of SGLT2 inhibition on glycemia, major adverse cardiovascular events, hospitalization for heart failure, and renal endpoints in diabetes.
• Summarize the evolving landscape of evidence related to SGLT2 inhibition in patients without diabetes.

Speaker: 

Mark Sanford, NP, CDE

This webinar is brought to you through a partnership with AstraZeneca.